Načítá se...
Early inhibitors of human cytomegalovirus: State-of-art and therapeutic perspectives
Human cytomegalovirus (HCMV) infection is associated with severe morbidity and mortality in immunocompromised individuals, mainly transplant recipients and AIDS patients, and is the most frequent cause of congenital malformations in newborn children. To date, few drugs are licensed for the treatment...
Uloženo v:
| Vydáno v: | Pharmacol Ther |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier Inc.
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7112563/ https://ncbi.nlm.nih.gov/pubmed/21570424 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2011.04.007 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|